Validation and Refinement of the Baveno VI Criteria for Ruling Out High-Risk Varices

Hong Zhou, Han Hu, Maoyong Tian, Jun Chu, Caiyun Tian, Yanqing Yang, and Shide Lin

1Department of Infectious Diseases, Affiliated Hospital of Zunyi Medical University, 201 Dalian Street, Guizhou 563003, China
2Department of Infectious Diseases, Suining Central Hospital, 127 Desheng Street, Suining, Sichuan 629000, China
3Department of Infectious Diseases, Xishui County People’s Hospital, Xiangjiang Street, Xishui, Guizhou 564600, China

Correspondence should be addressed to Shide Lin; linshide6@hotmail.com

Received 23 June 2020; Revised 2 November 2020; Accepted 17 November 2020; Published 9 December 2020

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the past decade, numerous studies have evaluated the roles of noninvasive methods for diagnosing or excluding varices and high-risk varices in patients with liver cirrhosis. The Baveno VI criteria recommend the use of a simple algorithm based on a liver stiffness measurement < 20 kPa through transient elastography and a platelet count > 150 × 10^9/L for ruling out high-risk varices in patients with compensated advanced chronic liver disease. A large number of studies have validated the clinical usefulness of Baveno VI criteria for excluding high-risk varices. Several strategies have been proposed to refine the Baveno VI criteria; however, currently there is no review to summarize the diagnostic accuracy and limitations of the Baveno VI criteria after extensive validation. In this review, we summarize the diagnostic accuracy and limitations of the Baveno VI criteria after extensive validation. We also discuss methods to refine these criteria.

1. Introduction

Portal hypertension (PH) is defined by a hepatic venous pressure gradient (HVPG) > 5 mmHg [1]. PH is responsible for the development and progression of the majority of severe complications of liver cirrhosis, such as ascites, esophageal varices (EV), esophagogastric variceal bleeding (EVB), and hepatic encephalopathy [2]. EVB is a common complication in patients with liver cirrhosis associated with high mortality. Either beta-blocker therapy or band ligation for the primary prophylaxis of EVB has been confirmed to reduce the bleeding rate by 50% in patients with high-risk varices (HRV) (i.e., medium/large EV or the presence of red signs on varices of any grade) [3, 4]. Therefore, screening for HRV is mandatory in the management of patients with liver cirrhosis [2, 5, 6].

Screening through gastroscopy has been recommended for the assessment of EV and bleeding risk following the diagnosis of liver cirrhosis [2, 4, 7, 8]. However, gastroscopy is an invasive and expensive procedure associated with risks [9]. In the past decade, owing to advances in the noninvasive diagnostic methods of liver cirrhosis, an increased number of patients with liver cirrhosis were diagnosed at an early stage [10, 11]. The prevalence of HRV in patients with early liver cirrhosis is very low; hence, most screening gastroscopies yield negative findings. Noninvasive screening methods for the diagnosis or exclusion of EV or HRV are promising for the avoidance of unnecessary gastroscopies [12–14].

The Baveno VI criteria recommended using liver stiffness measurement (LSM) < 20 kPa through transient elastography (TE) and a platelet (PLT) count > 150 × 10^9/L for ruling out HRVs in patients with compensated advanced chronic liver disease (cACLD) [7]. Following the introduction of the Baveno VI criteria, a large number of studies evaluated their value in excluding HRV in patients with cACLD or compensated liver cirrhosis.

In the evaluation of the usefulness of Baveno VI criteria for excluding HRVs, one of the most important index is the efficacy of Baveno VI criteria, which is reflected by the rate of spared endoscopy, that is, how many patients without HRVs will be spared from endoscopy; another important
index is its safety, that is, how many patients with HRVs will be misclassified. Baveno VI criteria defined the acceptable threshold of the rate of missed HRV as 5%, but did not state the method used to calculate it. Three different methods to calculate missed HRV rate have been used [15]. In all of them, the numerator was the number of missed HRVs, but the denominator was either of the following: the number of spared endoscopies, the number of HRVs, or the whole patient population. The rate of missed HRVs/spared endoscopies corresponds to 1 – negative predictive value (NPV) of Baveno VI criteria and is the most used index; however, a recent study found that it did not correctly reflect the clinical benefit of Baveno VI criteria [15]. The rate of missed HRVs/total HRVs corresponds to 1 – sensitivity of Baveno VI criteria and provides the true proportion of missed HRVs. The rate of missed HRVs/the number of all patients provides the prevalence of missed HRVs. It is suggested that both the rates of missed HRVs/spared endoscopies and missed HRVs/total HRVs be reported in the evaluation of Baveno VI criteria [15]; however, most previous studies did not report the rate of missed HRVs/total HRVs. Therefore, in this review, we summarized both the rates of missed HRVs/spared endoscopies and missed HRVs/total HRVs to evaluate the benefits and the limitations of Baveno VI criteria for excluding HRVs.

2. Pathogenesis and Epidemiology of PH and Varices

The prevalence of EV among patients with compensated cirrhosis is about 30%~40%, whereas it is up to 85% among patients with decompensated cirrhosis. In patients with compensated cirrhosis, EV develops at a rate of 7%~8% per year, and progresses from small to large varices at a rate of 10%~12% per year. The incidence of EVB is approximately 10% to 15% per year in patients with HRV. Six-week mortality of EVB ranges between 15% and 25% [2].

In patients with liver cirrhosis, the portal pressure is increased due to the increased intrahepatic resistance and portal system blood flow [16]. The structural alterations in the cirrhotic liver, such as sinusoidal fibrosis, regenerative nodules, and functional vasoconstriction of the intrahepatic circulation, contribute to the increase in intrahepatic resistance [17]. Increased intrahepatic fibrosis is the primary factor leading to increased HVPG in the early stage of progression of liver fibrosis. At this stage, there is a good correlation between the grades of liver fibrosis and levels of portal pressure [18]. The HVPG critical threshold of 10 mmHg has been defined as clinically significant PH owing to the occurrence of complications of PH over this threshold. When the HVPG reaches this threshold, the increased portal system blood flow (as a result of splanchic arterial vasodilation) further aggravates PH [19]. Therefore, when HVPG exceeds 10 mmHg, the level of portal pressure is not completely correlated with the grades of liver fibrosis [20].

Anatomical, physical, and biological factors play an important role in the development and progression of esophageal and gastric varices [17, 21]. Varices are considered the result of the opening and dilatation of vessels between the portal and systemic circulation due to the increased portal pressure [20]. Recent studies suggested that active angiogenesis also modulated the formation of varices [22, 23]. The risks of EVB are determined by the pressure of the intravariceal and esophageal lumen, as well as the radius and the thickness of the variceal wall. As the portal pressure increases, the variceal size increases and the wall thickness decreases. Therefore, the most important determining factor of EVB is the level of HVPG [24, 25]. HVPG > 12 mmHg is a strong predictor of EVB. As the Child-Pugh C class often reflects a higher portal pressure and red color signs on gastroscopy typically indicate an area with thin variceal wall, they are also risk factors for EVB [23].

3. The Validation of Baveno VI Criteria

In patients with chronic liver diseases, the progression of liver fibrosis is a continuous process. cACLD is a significant stage in this process, as clinically significant PH and varices may develop during this stage [26, 27]. The Baveno VI consensus recommended using LSM through TE to identify cACLD. LSM = 10 – 15 kPa and LSM > 15 kPa are suggestive (needing further test for confirmation) and highly suggestive of cACLD, respectively [7].

Screening for HRV is important for evaluating the prognosis and selecting appropriate treatment methods for patients with cACLD [28]. The Baveno VI criteria recommended using LSM < 20 kPa through TE and a PLT count > 150 × 10^9/L for ruling out HRVs in patients with cACLD [7]. Several advantages associated with the use of the Baveno VI criteria to stratify the risk of EV have been reported.

One of the major advantages of using the Baveno VI criteria to rule out HRV is their high reliability and safety. As shown in Table 1, applying this standard to patients with cACLD or compensated liver cirrhosis resulted in a risk to miss HRV < 5%, despite the rate of spared gastroscopies being approximately 8.1–46.2%. In a recent meta-analysis, which included 30 studies (8469 participants), the Baveno VI criteria for excluding HRVs had a pooled sensitivity and specificity of 97% and 32%, respectively. Among 1000 patients with cACLD and a 20% prevalence of HRVs, the Baveno VI criteria would avoid 262 gastroscopies and miss only six patients with HRVs. Another meta-analysis, including 13 studies and 4464 patients with cACLD, yielded similar results; the pooled rate of missing HRV was 0.3% and 32.8% of the gastroscopies could be avoided. The sensitivity, specificity, and area under the receiver operating curve of the Baveno VI criteria were 97%, 41%, and 96%, respectively [29]. These studies demonstrated that the Baveno VI criteria is a reliable method for stratifying the risk of EV and sparing gastroscopies in patients with cACLD or compensated cirrhosis.

Another advantage of the Baveno VI criteria is that they maintain high discriminating accuracy for ruling out HRVs in patients with different etiologies. The Baveno VI criteria for diagnosing cACLD or ruling out HRV have been based on data obtained mostly from patients with hepatitis C virus (HCV) or alcohol etiology. A few studies found that the optimal thresholds of LSM for diagnosing liver cirrhosis and discriminating EV and HRV are different between patients...
with different etiologies [30, 31]. However, subsequent studies reported that the Baveno VI criteria could be used to safely rule out HRVs in patients with nonalcoholic fatty liver disease (NAFLD), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC). Petta et al. evaluated the Baveno VI criteria in patients with NAFLD-related compensated cirrhosis [32]. The results showed that gastroscopies could be spared in 106 of the 314 patients (33.8%) and only one patient (0.9%) had HRV. Moctezuma-Velazquez et al. retrospectively investigated 227 patients with cACLD due to PBC and PSC, with a 13% prevalence of HRV. The Baveno VI criteria spared 30% and 30% of gastroscopies in patients with PBC and PSC, respectively, without missing HRV [33].

As demonstrated by two recent preliminary studies, the Baveno VI criteria can be used for the screening and surveillance of PH in patients with HBV- or HCV-associated liver cirrhosis receiving antiviral therapy. In patients with HCV- or HBV-related cirrhosis, elimination of HCV and inhibition of HBV DNA replication through antiviral treatment are associated with the improvement of fibrosis and a decline in portal pressure, finally resulting in a significant decrease in liver-related complications [35, 36]. The Baveno VI criteria were established based on patients with active HCV or HBV replication. The predictive value for HRVs in patients with sustained virological response (SVR) to antiviral therapy remains unknown. Thabut et al. evaluated the Baveno

| Author          | Research population (n, etiology) | Prevalence of HRV (n, %) | Spared endoscopy | Missed HRVs/saved endoscopies | Missed HRVs/total HRVs |
|-----------------|-----------------------------------|--------------------------|------------------|-------------------------------|------------------------|
| Maurice [48]    | 310, mixed                        | 15 (5%)                  | 102/310 (33.0%)  | 2/102 (2.0%)                  | 2/15 (13.3%)           |
| Jangouk [66]    | 262, mixed US cohort (161)        | 14 (9%)                  | 41/161 (25.4%)   | 0/41 (0%)                     | 0/14 (0%)              |
| Sousa [72]      | 104, mixed                        | 9 (9%)                   | 48/104 (46.2%)   | 0/48 (0%)                     | 0/9 (0%)               |
| Wong [58]       | 127, mixed                        | 11 (9%)                  | 105/127 (82.7%)  | 1/105 (1.0%)                  | 1/11 (9.1%)            |
| Petta [32]      | Training cohort (314)             | 32 (10%)                 | 106/314 (33.8%)  | 1/106 (0.9%)                  | 1/32 (3.1%)            |
|                  | Validation cohort (338)           | 45 (13%)                 | 113/338 (33.4%)  | 5/113 (4.4%)                  | 5/45 (11.1%)           |
| Bae [51]        | 282, mixed                        | 55 (20%)                 | 78/282 (27.6%)   | 3/78 (3.8%)                   | 3/55 (5.5%)            |
| Colecchia [63]  | Internal cohort (240)             | 46 (19%)                 | 52/240 (21.7%)   | 1/52 (1.9%)                   | 1/46 (2.2%)            |
|                  | External cohort (115)             | 15 (13%)                 | 19/115 (16.5%)   | 0/19 (0%)                     | 0/15 (0%)              |
| Tosetti [68]    | 442, mixed                        | 31 (7%)                  | 86/442 (19.5%)   | 0/86 (0%)                     | 0/31 (0%)              |
| Lee [53]        | 1218, mixed                       | 249 (20%)                | 313/1218 (25.7%) | 6/313 (1.9%)                  | 6/249 (2.4%)           |
| Stefanescu [64] | 185, mixed                        | 43 (23%)                 | 15/185 (8.1%)    | 0/15 (0%)                     | 0/43 (0%)              |
| Gaete [73]      | 300, mixed                        | 54 (18%)                 | 95/300 (31.7%)   | 1/95 (1.1%)                   | 1/54 (1.9%)            |
| Moctezuma-Velazquez [33] | 227, PBC, PSC | 30 (13%) | 82/227 (36.1%) | 0/82 (0%) | 0/30 (0%) |
| Protopapas [71] | 107, mixed                        | 22 (21%)                 | 13/107 (12.1%)   | 0/13 (0%)                     | 0/22 (0%)              |

Note: HRV—high-risk varices; NAFLD—nonalcoholic fatty liver disease; PBC—primary biliary cholangitis; PSC—primary sclerosing cholangitis.
VI criteria in patients with compensated liver cirrhosis due to HBV or HCV infection, and with or without a sustained response to antiviral therapy. They found that, at the time of PH progression (as the onset of HRV- or PH-related bleeding), all patients exhibited worsening of their Baveno VI status [37]. In another study, Puigvehi et al. investigated 230 patients with liver cirrhosis due to HCV and SVR after treatment with direct-acting antivirals. The NPV of the Baveno VI criteria to exclude HRV was maintained after SVR [38]. These results suggested that the Baveno VI criteria can be used for the screening and surveillance of PH in patients with HBV- or HCV-associated liver cirrhosis receiving antiviral therapy.

4. Limitation of the Baveno VI Criteria

As shown in Table 1, the Baveno VI criteria spare only approximately 8.1–46.2% of the gastroscopies. Of note, >40% of unnecessary gastroscopies cannot be spared in patients with cACLD. This is attributed to the low specificity of the Baveno VI criteria for ruling out HRV, which results in a large number of unnecessary gastroscopies. In a meta-analysis, 74% of patients with cACLD did not meet the Baveno VI criteria and were referred for screening endoscopy to detect the possible presence of HRVs. However, the majority of these patients (74%) did not have HRVs [34].

Several factors that may influence the rate of spared gastroscopies have been investigated. A meta-analysis found a negative correlation of the proportion of viral liver disease, as well as the levels of alanine amino transferases (ALT) and aspartate amino transferases, with the rate of spared endoscopy [29]. In patients with HBV infection, the diagnostic thresholds of LSM for cACLD and liver cirrhosis are lower than those in patients with other etiologies. Therefore, the risk of having HRVs in HBV patients with LSM < 20 kPa and a PLT count > 150 × 10^9/L is higher than that in patients with other etiologies [39]. A positive correlation between the proportion of NAFLD and rate of spared endoscopy was reported [29]. In a previous study, we found that, among patients with HBV-related compensated liver cirrhosis who did not meet the Baveno VI criteria, the prevalence of HRV was significantly lower in those with ALT or total bilirubin (TBil) ≥ 2 upper limit of normal (ULN) (14.3%) than in those with both ALT and TBil < 2 ULN (34.1%) [40]. These findings suggested that the concomitant liver inflammation may falsely increase LSM, making it difficult for patients to fulfill the Baveno VI criteria and decreasing the rate of spared gastroscopies.

Another limitation of the Baveno VI criteria is that LSM may not be reliable in ≤20% of patients. LSM is affected by the position of the probe [41], concomitant liver inflammation [42], intra- and extrahepatic cholestasis [43], body mass index [44], the experience of the operator, etc. [45, 46]. In addition, LSM also showed high variation, especially in patients with high LSM values [47]. A recent study suggested that performing two LSMS on different days, as recommended by the Baveno VI criteria, may improve the diagnostic accuracy [47]. However, undergoing two TE examinations within a short period of time may not be acceptable to patients. Among a large number of studies concerned with the evaluation of the Baveno VI criteria, few studies had implemented the two-LSM approach.

Several factors, other than PH, may also have a significant impact on PLT. In a study reported by Maurice et al., two patients with HRV were missed by the Baveno VI criteria, and one of those had a previous splenectomy [48]. Furthermore, LSM through TE may not be easily available in developing countries, limiting the use of the Baveno VI criteria.

As shown in Table 1, the other limitation of the Baveno VI criteria is that in a few studies the rate of missed HRVs/total HRVs exceeded 5% [48–51]. If more stringent criteria of the missed HRVs/total HRV < 5% is adopted, the Baveno VI criteria is unreliable in these studies. The rate of missed HRVs/total HRVs corresponds to sensitivity (1 – sensitivity) for HRVs and provides the true proportion of missed HRVs. These findings indicate that the sensitivity of Baveno VI criteria is not as high as its NPV for excluding HRVs.

5. Refinement of the Baveno VI Criteria

Several studies have attempted to overcome the limitations of the Baveno VI criteria. The strategies applied for the refinement of these criteria include adjustment of the LSM and PLT thresholds and combination with other predictors (Table 2).

Several thresholds of the LSM (25–30 kPa) and PLT count (100–120 × 10^9/L) have been examined to increase the rate of spared gastroscopies. The most broadly studied criteria were LSM 25/PLT 110 (Expanded Baveno VI). Augustin et al. increased the threshold of LSM to <25 kPa and decreased that of the PLT count to >110 × 10^9/L in patients with cACLD of different etiologies [52]. The Expanded Baveno VI criteria increased the rate of spared gastroscopies from 21% to 40% compared with the Baveno VI criteria, with a 0.6% risk of missing HRV. The refined criteria also performed well in patients with cACLD of different etiologies. However, the rate of missed HRVs/total HRV increased to 6.5%. Bae et al. found that, in patients with cACLD due to HBV infection, the Expanded Baveno VI criteria could spare more gastroscopies than the Baveno VI criteria (51.7% vs. 27.6%, respectively) and could miss more HRVs (6.8% vs. 3.8%, respectively) [51]. In another study including patients with chronic HBV infection, the Expanded Baveno VI criteria missed >5% of HRVs [53]. In a meta-analysis, Staflidou et al. found that the Expanded Baveno VI criteria could further reduce the rate of unnecessary gastroscopies compared with the Baveno VI criteria (42.8% vs. 26.2%, respectively) and could be associated with a higher rate of missed HRVs (5% vs. 2%, respectively) [34].

Ding et al. found that gastroscopies could be avoided in a total of 107 patients (39%) with the combination of LSM ≤ 25 kPa and a PLT count ≥ 100 × 10^9/L, having a NPV of 100% [54]. However, in another study of patients with HCV infection, these criteria missed 10% of the total HRVs [55]. Several studies attempted to identify the optimal excluding criteria for HRVs in patients with different etiologies. Petra et al. proposed a set of NAFLD cirrhosis criteria: PLT count > 110 × 10^9/L and LSM < 30 kPa for the M probe, and PLT count > 110 × 10^9/L and LSM < 25 kPa for the XL probe.
| Author        | Patients | Criteria                              | Prevalence of HRV (n, %) | Spared endoscopy (%) | Missed HRVs/saved endoscopies | Missed HRVs/total HRVs |
|--------------|----------|---------------------------------------|--------------------------|----------------------|-------------------------------|------------------------|
| Ding [54]    | 271, mixed| LSM ≤ 25 + PLT ≥ 100                   | 26 (10%)                 | 107/271 (39%)        | 0/107 (0%)                    | 0/26 (0%)              |
|              |          | Baveno VI                            | 14 (9%)                  | 41/161 (25.4%)       | 0/41 (0%)                     | 0/14 (0%)              |
|              |          | LSM ≤ 25 + PLT ≥ 100                   | 55 (15%)                 | 149/368 (40.5%)      | 10/149 (6.7%)                  | 10/55 (18.2%)          |
| Puigvehi [55]| 368, HCV | LSM ≤ 25 + PLT ≥ 100                   | 26 (10%)                 | 107/271 (39%)        | 0/107 (0%)                    | 0/26 (0%)              |
|              |          | Baveno VI                            | 14 (9%)                  | 41/161 (25.4%)       | 0/41 (0%)                     | 0/14 (0%)              |
| Jangouk [66] | 262, mixed| LSM ≤ 25 + PLT ≥ 100                   | 17 (10%)                 | 16/101 (15.8%)       | 0/16 (0%)                     | 0/17 (0%)              |
|              |          | Baveno VI                            | 17 (10%)                 | 28/101 (27.7%)       | 0/28 (0%)                     | 0/17 (0%)              |
| Augustin [52]| 925, mixed| LSM ≤ 25 + PLT ≥ 100                   | 92 (10%)                 | 367/925 (40%)        | 6/367 (1.6%)                   | 6/92 (6.5%)            |
|              |          | LSM < 25 + PLT > 110 + MELD = 6       | 92 (10%)                 | 405/883 (45.8%)      | 7/405 (1.7%)                   | 7/92 (7.6%)            |
|              |          | Baveno VI                            | 32 (10%)                 | 106/314 (33.8%)      | 1/106 (0.9%)                   | 1/32 (3.1%)            |
|              |          | LSM < 25 + PLT > 110                  | 32 (10%)                 | 182/314 (58%)        | 7/182 (3.8%)                   | 7/32 (21.9%)           |
|              |          | LSM < 30 + PLT > 110                  | 32 (10%)                 | 215/314 (68.5%)      | 9/215 (4.2%)                   | 9/32 (28.1%)           |
| Petta [32]   | 790, NAFLD| LSM < 25 + PLT > 110 + MELD = 6       | 45 (10%)                 | 113/338 (33.4%)      | 5/113 (4.4%)                   | 5/45 (11.1%)           |
|              |          | Baveno VI                            | 45 (13%)                 | 183/338 (54.1%)      | 8/183 (4.4%)                   | 8/45 (17.8%)           |
|              |          | LSM < 25 + PLT > 110                  | 45 (13%)                 | 209/338 (61.8%)      | 10/209 (4.8%)                  | 10/45 (22.2%)          |
|              |          | LSM < 25 + PLT > 110                  | 45 (13%)                 | 209/338 (61.8%)      | 10/209 (4.8%)                  | 10/45 (22.2%)          |
|              |          | LSM < 30 + PLT > 110                  | 45 (13%)                 | 209/338 (61.8%)      | 10/209 (4.8%)                  | 10/45 (22.2%)          |
|              |          | Validation cohort:                    |                          |                      |                              |                        |
|              |          | Bareno VI                            | 32 (10%)                 | 106/314 (33.8%)      | 1/106 (0.9%)                   | 1/32 (3.1%)            |
|              |          | LSM < 25 + PLT > 110                  | 32 (10%)                 | 182/314 (58%)        | 7/182 (3.8%)                   | 7/32 (21.9%)           |
|              |          | LSM < 30 + PLT > 110                  | 32 (10%)                 | 215/314 (68.5%)      | 9/215 (4.2%)                   | 9/32 (28.1%)           |
| Bae [51]     | 282, mixed| LSM < 25 + PLT > 110                  | 14 (10%)                 | 64/138 (46.4%)       | 1/64 (1.6%)                    | 1/14 (7.1%)            |
|              |          | Baveno VI                            | 55 (20%)                 | 78/282 (27.6%)       | 3/78 (3.8%)                    | 3/55 (5.5%)            |
|              |          | LSM < 25 + PLT > 110                  | 55 (20%)                 | 146/282 (51.7%)      | 10/146 (6.8%)                  | 10/55 (18.2%)          |
|              |          | Validation cohort:                    |                          |                      |                              |                        |
|              |          | Bareno VI                            | 14 (10%)                 | 64/138 (46.4%)       | 1/64 (1.6%)                    | 1/14 (7.1%)            |
|              |          | LSM < 25 + PLT > 110                  | 55 (20%)                 | 78/282 (27.6%)       | 3/78 (3.8%)                    | 3/55 (5.5%)            |
| Colecchia [63]| 498, mixed| LSM < 25 + PLT > 110                  | 46 (19%)                 | 52/240 (21.7%)       | 1/52 (1.9%)                    | 1/46 (2.2%)            |
|              |          | Baveno VI                            | 46 (19%)                 | 86/240 (35.8%)       | 1/86 (1.2%)                    | 1/46 (2.2%)            |
|              |          | LSM < 25 + PLT > 110                  | 46 (19%)                 | 86/240 (35.8%)       | 1/86 (1.2%)                    | 1/46 (2.2%)            |
|              |          | Internal cohort:                      |                          |                      |                              |                        |
|              |          | Bareno VI                            | 46 (19%)                 | 52/240 (21.7%)       | 1/52 (1.9%)                    | 1/46 (2.2%)            |
|              |          | SSM ≤ 46                              | 46 (19%)                 | 86/240 (35.8%)       | 1/86 (1.2%)                    | 1/46 (2.2%)            |
|              |          | Validation cohort:                    |                          |                      |                              |                        |
|              |          | Bareno VI                            | 15 (13%)                 | 19/115 (16.5%)       | 0/19 (0%)                      | 0/15 (0%)              |
|              |          | SSM ≤ 46                              | 15 (13%)                 | 35/115 (30.4%)       | 0/35 (0%)                      | 0/15 (0%)              |
| Author      | Patients | Criteria                              | Prevalence of HRV (n, %) | Spared endoscopy (%) | Missed HRVs/saved endoscopies | Missed HRVs/total HRVs |
|-------------|----------|---------------------------------------|--------------------------|----------------------|------------------------------|------------------------|
| Tosetti [68]| 442, mixed| Baveno VI + SSM ≤ 46                  | 15 (13%)                 | 43/115 (37.4%)       | 0/43 (0%)                    | 0/15 (0%)              |
|             |          | Baveno VI                             | 31 (7%)                  | 86/442 (19.5%)       | 0/86 (0%)                    | 0/31 (0%)              |
|             |          | LSM < 25 + PLT > 110                  | 31 (7%)                  | 193/442 (43.7%)      | 0/193 (0%)                   | 0/31 (0%)              |
|             |          | LSM < 25 + PLT > 125                  | 31 (7%)                  | 154/442 (34.8%)      | 0/154 (0%)                   | 0/31 (0%)              |
|             |          | PLT > 150 + MELD = 6                  | 31 (7%)                  | 171/442 (38.7%)      | 3/171 (1.8%)                 | 3/31 (9.7%)            |
|             |          | Baveno VI                             | 249 (20%)                | 313/1218 (25.7%)     | 6/313 (1.9%)                 | 6/249 (2.4%)           |
|             |          | LSM < 20 + PLT > 110                  | 249 (20%)                | 476/1218 (39.1%)     | 21/476 (4.4%)                | 21/249 (8.4%)          |
|             |          | LSM < 25 + PLT > 120                  | 249 (20%)                | 476/1218 (39.1%)     | 23/476 (4.8%)                | 23/249 (9.2%)          |
|             |          | LSM < 25 + PLT > 110                  | 249 (20%)                | 530/1218 (43.5%)     | 31/530 (5.8%)                | 31/249 (12.4%)         |
|             |          | LSM < 30 + PLT > 150                  | 249 (20%)                | 381/1218 (31.3%)     | 16/381 (4.2%)                | 16/249 (6.4%)          |
|             |          | LSM < 4.47                            | 249 (20%)                | 536/1218 (44.0%)     | 23/536 (4.3%)                | 23/249 (9.2%)          |
|             |          | Baveno VI                             | 43 (23%)                 | 15/185 (8.1%)        | 0/15 (0%)                    | 0/43 (0%)              |
|             |          | LSM < 30 + PLT > 150                  | 43 (23%)                 | 49/185 (26.5%)       | 2/49 (4.1%)                  | 2/43 (4.7%)            |
|             |          | LSM < 4.47                            | 43 (23%)                 | 72/185 (38.9%)       | 2/72 (2.8%)                  | 2/43 (4.7%)            |
| Stefanescu [64]| 185, mixed| Baveno VI + SSM@50 Hz : 40.1         | 43 (23%)                 | 49/185 (26.5%)       | 2/49 (4.1%)                  | 2/43 (4.7%)            |
|             |          | Baveno VI + SSM@100 Hz : 41.3        | 43 (23%)                 | 72/185 (38.9%)       | 2/72 (2.8%)                  | 2/43 (4.7%)            |
| Protopapas [71]| 107, mixed| PLT/log₁₀LSM                          | 22 (21%)                 | 22/107 (20.6%)       | 0/22 (0%)                    | 0/22 (0%)              |

Note: HCV—hepatitis C virus; HRV—high-risk varices; LSM—liver stiffness measurement; LSPS—liver stiffness-spleen diameter to platelet ratio score; MELD—model for end-stage liver disease; NAFLD—nonalcoholic fatty liver disease; PLT—platelet; SSM—spleen stiffness measurement.
Several studies attempted to predict HRV without using LSM or SSM to overcome the limitation of unavailable TE in some hospitals. Jangouk et al. recently reported a 12% increase in the rate of spared gastroscopies (without additional HRV missed) by expanding the Baveno VI criteria to patients with model for end-stage liver disease (MELD) = 6 [66]. In addition, a stepwise strategy using PLT count > 150 x 10^9/L and MELD = 6 without LSM substantially increased the number of avoided gastroscopies, maintaining a very low rate of missed HRVs. Although some studies confirmed the accuracy of this approach [67], a recent study reported contradictory results (missing approximately 10% of HRVs) [68]. Calvaruso et al. found that, among 1381 patients with HCV-associated cirrhosis, a PLT count cut-off value of >120 x 10^9/L and a serum albumin level > 36 g/L were able to identify patients without medium/large EV [69]. Moreover, the NPV was slightly higher than that observed for the Baveno VI and Expanded Baveno VI criteria.

Calés et al. developed a strategy for the diagnosis of large esophageal varices in patients with compensated liver cirrhosis [70], which involved the sequential combination of a blood test and esophageal capsule endoscopy (ECE). This strategy significantly increased spared endoscopy rates compared to that of the Baveno VI criteria. However, its applicability requires validation and ECE cost optimization.

Recently, Protopapas et al. used PLT/log_{10}LSM to refine Baveno VI criteria [71], and they found that PLT/log_{10}LSM ≤122,000 μL^{-1} x kPa^{-1} predicted HRV with 100% sensitivity and negative predictive value (NPV), sparing 22 (20.6%) of the patients from unneeded screening endoscopy without missing HRVs.

As shown in Table 2, although most of these refining criteria improved the rate of spared gastroscopies, they also missed more HRVs than that of Baveno VI criteria, especially the rate of missed HRVs/total HRVs which showed a great variability in these studies. In addition, most of these refining criteria still need extensive validation in future studies.

6. Conclusion

After extensive validation, the Baveno VI criteria exhibited high reliability for safely ruling out HRVs and avoiding unnecessary gastroscopies. However, its efficacy for excluding patients with HRVs remains unsatisfactory: >40% of unnecessary gastroscopies cannot be spared through the use of the Baveno VI criteria in patients with CACLD. Several strategies have been proposed to refine the Baveno VI criteria, and most of them improved the rate of spared gastroscopies. However, their accuracy requires further validation.

In clinical practice, Baveno VI criteria is currently the only reliable method and can be used to screen HRVs in patients with compensated liver cirrhosis with most common etiologies. The refined Baveno VI criteria or the criteria without LSM is not suitable for screening HRVs.

Data Availability

The data used to support the findings of this study are included within the article.
Conflicts of Interest

The authors declare that they have no conflicts of interest in this study.

Authors’ Contributions

Hong Zhou and Han Hu contributed equally to this work.

Acknowledgments

A Chinese National Natural Science Foundation Project was the source of support for this study (grant number: 81860114).

References

[1] J. D. Vorobioff and R. J. Groszmann, "Prevention of portal hypertension: from variceal development to clinical decompensation," *Hepatology*, vol. 61, no. 1, pp. 375–381, 2015.

[2] G. Garcia-Tsao, J. G. Abraldes, A. Berzigotti, and J. Bosch, "Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the american association for the study of liver diseases," *Hepatology*, vol. 65, pp. 310–335, 2016.

[3] E. Biecker, "Portal hypertension and gastrointestinal bleeding: diagnosis, prevention and management," *World Journal of Gastroenterology*, vol. 19, no. 31, pp. 5035–5050, 2013.

[4] D. Tripathi, A. J. Stanley, P. C. Hayes et al., "U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients," *Gut*, vol. 64, no. 11, pp. 1680–1704, 2015.

[5] G. Garcia-Tsao, A. J. Sanyal, N. D. Grace, W. Carey, and Practice Guidelines Committee of the American Association for the Study of Liver Diseases, the Practice Parameters Committee of the American College of Gastroenterology, "Prevention and management of gastrointestinal varices and variceal hemorrhage in cirrhosis," *Hepatology*, vol. 46, no. 3, pp. 922–938, 2007.

[6] H. Fukui, H. Saito, Y. Ueno et al., "Evidence-based clinical practice guidelines for liver cirrhosis 2015," *Journal of Gastroenterology*, vol. 51, pp. 629–650, 2016.

[7] R. de Franchis, "Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension," *Journal of Hepatology*, vol. 63, no. 3, pp. 743–752, 2015.

[8] R. de Franchis, "Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension," *Journal of Hepatology*, vol. 53, no. 4, pp. 762–768, 2010.

[9] I. Dzeletovic and T. H. Baron, "History of portal hypertension and endoscopic treatment of esophageal varices," *Gastrointestinal Endoscopy*, vol. 75, no. 6, pp. 1244–1249, 2012.

[10] C. Bureau, S. Metivier, J. M. Peron et al., "Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease," *Alimentary Pharmacology & Therapeutics*, vol. 27, no. 12, pp. 1261–1268, 2008.

[11] M. Y. Kim, W. K. Jeong, and S. K. Baik, "Invasive and non-invasive diagnosis of cirrhosis and portal hypertension," *World Journal of Gastroenterology*, vol. 20, no. 15, pp. 4300–4315, 2014.

[12] G. Sebastiani, D. Tempesta, G. Fattovich et al., "Prediction of esophageal varices in hepatic cirrhosis by simple serum non-invasive markers: results of a multicenter, large-scale study," *Journal of Hepatology*, vol. 53, no. 4, pp. 630–638, 2010.

[13] A. Berzigotti, E. Ashkenazi, E. Reverter, J. G. Abraldes, and J. Bosch, "Non-invasive diagnostic and prognostic evaluation of liver cirrhosis and portal hypertension," *Disease Markers*, vol. 31, no. 3, 138 pages, 2011.

[14] J. V. Cherian, N. Deepak, R. P. Ponnuasamy, A. Somasundaram, and V. Jayanthi, "Non-invasive predictors of esophageal varices," *Saudi Journal of Gastroenterology*, vol. 17, no. 1, pp. 64–68, 2011.

[15] P. Calès, F. Buissen, F. Ravaiol, et al., "How to clarify the Baveno VI criteria for ruling out varices needing treatment by noninvasive tests," *Liver International*, vol. 39, no. 1, pp. 49–53, 2019.

[16] Y. Iwakiri and R. J. Groszmann, "Vascular endothelial dysfunction in cirrhosis," *Journal of Hepatology*, vol. 46, no. 5, pp. 927–934, 2007.

[17] L. Turco and G. Garcia-Tsao, "Portal hypertension: pathogenesis and diagnosis," *Clinics in Liver Disease*, vol. 23, no. 4, pp. 573–587, 2019.

[18] A. Berzigotti, "Non-invasive evaluation of portal hypertension using ultrasound elastography," *Journal of Hepatology*, vol. 67, no. 2, pp. 399–411, 2017.

[19] M. Bolognesi, M. Di Pascoli, A. Verardo, and A. Gatta, "Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis," *World Journal of Gastroenterology*, vol. 20, no. 10, pp. 2555–2563, 2014.

[20] Y. Iwakiri, "Pathophysiology of portal hypertension," *Clinics in Liver Disease*, vol. 18, no. 2, pp. 281–291, 2014.

[21] D. A. Simonetto, M. Liu, and P. S. Kamath, "Portal hypertension and related complications: diagnosis and management," *Mayo Clinic Proceedings*, vol. 94, no. 4, pp. 714–726, 2019.

[22] D. V. Garbuzenko, N. O. Arefyev, and E. L. Kazachkova, "Anti-angiogenic therapy for portal hypertension in liver cirrhosis: current progress and perspectives," *World Journal of Gastroenterology*, vol. 24, no. 33, pp. 3738–3748, 2018.

[23] J. Bosch, R. J. Groszmann, and V. H. Shah, "Evolution in the understanding of the pathophysiological basis of portal hypertension: how changes in paradigm are leading to successful new treatments," *Journal of Hepatology*, vol. 62, no. 1, pp. S121–S130, 2015.

[24] C. Ripoll, R. Groszmann, G. Garcia-Tsao et al., "Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis," *Gastroenterology*, vol. 133, no. 2, pp. 481–488, 2007.

[25] J. G. Abraldes, C. Villanueva, R. Bañares et al., "Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy," *Journal of Hepatology*, vol. 48, no. 2, pp. 229–236, 2008.

[26] European Association for the Study of the Liver, "EASL clinical practice guidelines for the management of patients with decompensated cirrhosis," *Journal of Hepatology*, vol. 69, pp. 406–460, 2018.

[27] E. A. Tschochatzis, J. Bosch, and A. K. Burroughs, "Liver cirrhosis," *The Lancet*, vol. 383, no. 9930, pp. 1749–1761, 2014.

[28] C. Ripoll, R. J. Groszmann, G. Garcia-Tsao et al., "Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis," *Journal of Hepatology*, vol. 50, no. 5, pp. 923–928, 2009.

[29] Z. Szakács, B. Eröss, A. Soós et al., "Baveno criteria safely identify patients with compensated advanced chronic liver disease
who can avoid variceal screening endoscopy: a diagnostic test accuracy meta-analysis,” *Frontiers in Physiology*, vol. 10, pp. 1028–1028, 2019.

[30] S. Singh, A. J. Muir, D. T. Dieterich, and Y. T. Falck-Ytter, “American Gastroenterological Association Institute technical review on the role of elastography in chronic liver diseases,” *Gastroenterology*, vol. 152, no. 6, pp. 1544–1577, 2017.

[31] E. Nguyen-Khac, P. Saint-Leger, B. Tramier, H. Coevoet, D. Capron, and J.-L. Dupas, “Noninvasive diagnosis of large esophageal varices by fibroscan: strong influence of the cirrhosis etiology,” *Alcoholism: Clinical and Experimental Research*, vol. 34, pp. 1146–1153, 2010.

[32] S. Petta, G. Sebastiani, E. Bugianesi et al., “Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis,” *Journal of Hepatology*, vol. 69, no. 4, pp. 878–885, 2018.

[33] C. Mocetuzuma-Velazquez, F. Saffioti, S. Tasayco-Huaman et al., “Non-invasive prediction of high-risk varices in patients with primary biliary cholangitis and primary sclerosing cholangitis,” *The American Journal of Gastroenterology*, vol. 114, no. 3, pp. 446–452, 2019.

[34] M. Stafylidou, P. Paschos, A. Katsoula et al., “Performance of Baveno VI and Expanded Baveno VI Criteria for Excluding High-Risk Varices in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis,” *Clinical Gastroenterology and Hepatology*, vol. 17, no. 9, pp. 1744–1755.e11, 2019.

[35] C.-Z. Li, L.-F. Cheng, Q.-S. Li, Z.-Q. Wang, and J.-H. Yan, “Antiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis,” *World Journal of Gastroenterology*, vol. 19, no. 40, pp. 6849–6856, 2013.

[36] P. Lampertico, F. Invernizzi, M. Viganò et al., “The long-term benefits of novaltis(t)ide analogs in compensated hBv cirtotic patients with no or small esophageal varices: a 12-year prospective cohort study,” *Journal of Hepatology*, vol. 63, no. 5, pp. 1118–1125, 2015.

[37] D. Thabut, C. Bureau, R. Layese et al., “Validation of Baveno VI criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy,” *Gastroenterology*, vol. 156, no. 4, pp. 997–1009.e5, 2019, e5.

[38] M. Puigvehí, M.-C. Londoño, X. Torras et al., “Impact of sustained virological response with DAAs on gastroesophageal varices and Baveno criteria in HCV-cirrhotic patients,” *Journal of Gastroenterology*, vol. 55, no. 2, pp. 205–216, 2020.

[39] J. Martinez-Camprecios, M. Pons, and J. Genesca, “Beyond Baveno VI: how far are we?,” *Digestive and Liver Disease*, vol. 51, no. 8, pp. 1141–1143, 2019.

[40] H. Zhou, J. Long, H. Hu, C. Y. Tian, and S. D. Lin, “Liver stiffness and serum markers for excluding high-risk varices in patients who do not meet Baveno VI criteria,” *World Journal of Gastroenterology*, vol. 25, no. 35, pp. 3523–3533, 2019.

[41] R. P. Myers, P. Crotty, G. Pomier-Layrargues, M. Ma, S. J. Urbanski, and M. Elkahab, “Prevalence, risk factors and causes of discordance in fibrosis staging by transient elastography and liver biopsy,” *Liver International*, vol. 30, no. 10, pp. 1471–1480, 2010.

[42] G. L.-H. Wong, V. W.-S. Wong, P. C.-L. Choi et al., “Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B,” *Journal of Gastroenterology and Hepatology*, vol. 24, no. 6, pp. 1002–1007, 2009.

[43] G. Millonig, F. M. Reimann, S. Friedrich et al., “Extrahepatic cholestasis increases liver stiffness (fibroscan) irrespective of fibrosis,” *Hepatology*, vol. 48, no. 5, pp. 1718–1723, 2008.

[44] S. Petta, M. Maida, F. S. Macaluso et al., “The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease,” *Hepatology*, vol. 62, no. 4, pp. 1101–1110, 2015.

[45] I. Mederacke, K. Wursthorn, J. Kirschner et al., “Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection,” *Liver International*, vol. 29, no. 10, pp. 1500–1506, 2009.

[46] G. Millonig, S. Friedrich, S. Adolff et al., “Liver stiffness is directly influenced by central venous pressure,” *Journal of Hepatology*, vol. 52, no. 2, pp. 206–210, 2010.

[47] J. C.-L. Chow, G. L.-H. Wong, A. W.-H. Chan et al., “Repeating measurements by transient elastography in non-alcoholic fatty liver disease patients with high liver stiffness,” *Journal of Gastroenterology and Hepatology*, vol. 34, no. 1, pp. 241–248, 2014.

[48] J. B. Maurice, E. Brodkin, F. Arnold et al., “Validation of the Baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic surveillance for varices,” *Journal of Hepatology*, vol. 65, no. 5, pp. 899–905, 2016.

[49] G. L. H. Wong, R. Kwok, H. L. Y. Chan et al., “Measuring spleen stiffness to predict varices in chronic hepatitis B cirrhotic patients with or without receiving non-selective beta-blockers,” *Journal of Digestive Diseases*, vol. 17, no. 8, pp. 538–546, 2016.

[50] S. Petta, V. W.-S. Wong, C. Cammà et al., “Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values,” *Hepatology*, vol. 65, no. 4, pp. 1145–1155, 2017.

[51] J. Bae, D. H. Sinn, W. Kang et al., “Validation of the Baveno VI and the expanded Baveno VI criteria to identify patients who could avoid screening endoscopy,” *Liver International*, vol. 38, no. 8, pp. 1442–1448, 2018.

[52] S. Augustin, M. Pons, J. B. Maurice et al., “Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease,” *Hepatology*, vol. 66, no. 6, pp. 1980–1988, 2017.

[53] H. A. Lee, S. U. Kim, Y. S. Seo et al., “Prediction of the varices needing treatment with non-invasive tests in patients with compensated advanced chronic liver disease,” *Liver International*, vol. 39, no. 6, pp. 1071–1079, 2019.

[54] N. S. Ding, T. Nguyen, D. M. Iser et al., “Liver stiffness plus platelet count can be used to exclude high-risk esophageal varices,” *Liver International*, vol. 36, no. 2, pp. 240–245, 2016.

[55] M. Puigvehí, M. C. Londoño, R. M. Morillas et al., “Platelet count and liver stiffness measurement to exclude high-risk gastroesophageal varices in patients with HCV-cirrhosis. A multicentric study,” *Journal of Hepatology*, vol. 64, no. 2, p. S273, 2016.

[56] G. I. Nedredal, M. Yin, T. McKenzie et al., “Portal hypertension correlates with splenic stiffness as measured with MR elastography,” *Journal of Magnetic Resonance Imaging*, vol. 34, no. 1, pp. 79–87, 2011.

[57] H. Abe, Y. Midorikawa, N. Matsumoto et al., “Prediction of esophageal varices by liver and spleen MR elastography,” *European Radiology*, vol. 29, no. 12, pp. 6611–6619, 2019.
[58] G. L. H. Wong, R. Kwok, A. J. Hui et al., “A new screening strategy for varices by liver and spleen stiffness measurement (LSSM) in cirrhotic patients: a randomized trial,” *Liver International*, vol. 38, no. 4, pp. 636–644, 2018.

[59] V. Calvaruso, F. Bronte, E. Conte, F. Simone, A. Craxì, and V. di Marco, “Modified spleen stiffness measurement by transient elastography is associated with presence of large oesophageal varices in patients with compensated hepatitis C virus cirrhosis,” *Journal of Viral Hepatitis*, vol. 20, no. 12, pp. 867–874, 2013.

[60] W. Manatsathit, H. Samant, S. Kapur et al., “Accuracy of liver stiffness, spleen stiffness, and LS-spleen diameter to platelet ratio score in detection of esophageal varices: systemic review and meta-analysis,” *Journal of Gastroenterology and Hepatology*, vol. 33, no. 10, pp. 1696–1706, 2018.

[61] A. Colecchia, L. Montrone, E. Scaioli et al., “Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis,” *Gastroenterology*, vol. 143, no. 3, pp. 646–654, 2012.

[62] P. Sharma, V. Kirnake, P. Tyagi et al., “Spleen stiffness in patients with cirrhosis in predicting esophageal varices,” *The American Journal of Gastroenterology*, vol. 108, no. 7, pp. 1101–1107, 2013.

[63] A. Colecchia, F. Ravaioli, G. Marasco et al., “A combined model based on spleen stiffness measurement and Baveno VI criteria to rule out high-risk varices in advanced chronic liver disease,” *Journal of Hepatology*, vol. 69, no. 2, pp. 308–317, 2018.

[64] H. Stefanescu, G. Marasco, P. Calès et al., “A novel spleen-dedicated stiffness measurement by FibroScan® improves the screening of high-risk oesophageal varices,” *Liver International*, vol. 40, pp. 175–185, 2019.

[65] N. Matsui, K. Imajo, M. Yoneda et al., “Magnetic resonance elastography increases usefulness and safety of non-invasive screening for esophageal varices,” *Journal of Gastroenterology and Hepatology*, vol. 33, no. 12, pp. 2022–2028, 2018.

[66] P. Jangouk, L. Turco, A. De Oliveira, F. Schepis, E. Villa, and G. Garcia-Tsao, “Validating, deconstructing and refining Baveno criteria for ruling out high-risk varices in patients with compensated cirrhosis,” *Liver International*, vol. 37, no. 8, pp. 1177–1183, 2017.

[67] S. Nawalerspanya, P. Sripongpun, N. Chamroonkul, C. Kongkamol, and T. Piratvisuth, “Validation of original, expanded Baveno VI, and stepwise & platelet-meld criteria to rule out varices needing treatment in compensated cirrhosis from various etiologies,” *Annals of Hepatology*, vol. 19, no. 2, pp. 209–213, 2020.

[68] G. Tosetti, M. Primignani, V. La Mura et al., “Evaluation of three "beyond Baveno VI" criteria to safely spare endoscopies in compensated advanced chronic liver disease,” *Digestive and Liver Disease*, vol. 51, no. 8, pp. 1135–1140, 2019.

[69] V. Calvaruso, I. Cacciola, A. Licata et al., “Is transient elastography needed for noninvasive assessment of high-risk varices? The real experience,” *The American Journal of Gastroenterology*, vol. 114, no. 8, pp. 1275–1282, 2019.

[70] P. Calès, S. Sacher-Huvelin, D. Valla et al., “Large oesophageal varice screening by a sequential algorithm using a cirrhosis blood test and optionally capsule endoscopy,” *Liver International*, vol. 38, no. 1, pp. 84–93, 2018.

[71] A. A. Protopapas, T. Mylopoulou, V. P. Papadopoulos, K. Vogiatzi, I. Goulis, and K. Mimidis, “Validating and expanding the Baveno VI criteria for esophageal varices in patients with advanced liver disease: a multicenter study,” *Annals of Gastroenterology*, vol. 33, no. 1, pp. 87–94, 2020.

[72] M. Sousa, S. Fernandes, L. Proença et al., “The Baveno VI criteria for predicting esophageal varices: validation in real life practice,” *Revista Española de Enfermedades Digestivas*, vol. 109, no. 10, pp. 704–707, 2017.

[73] M. I. Gaete, L. A. Diaz, A. Arenas et al., “Baveno VI and expanded Baveno VI criteria successfully predicts the absence of high-risk gastro-oesophageal varices in a chilean cohort,” *Liver International*, vol. 40, no. 6, pp. 1427–1434, 2020.